Have any questions?
Tel: +44 (0)208 447 8899
Fax: +44 (0)208 447 9292
Visit our Contact page
for more information.
ECO Animal Health is a British company with a global presence, focused on providing solutions to economically important respiratory and enteric diseases in pigs and poultry. Our products and knowledge improve the health and welfare of pigs and poultry.
ECO Animal Health specialises in high quality medicines for the treatment of important diseases in the livestock sector. We are dedicated to the research, development and marketing of strong, existing brands, differentiated generics and innovative new solutions. Our commitment to our customers is to provide them with products of a consistently high quality supported by customer-focused teams.
ECO Animal Health strives to provide best in class, scientifically proven, ethical solutions to optimise the health, productivity and wellbeing of pigs and poultry.
We aim to do this sustainably, working in partnership with animal health professionals and livestock producers bringing value to all by improving animal husbandry around the world.
The ECO Research and Development (R&D) function is aligned with ECO’s corporate objectives and focused on bringing innovative customer solutions for the prevention and treatment of enteric and respiratory diseases in pigs and poultry to the market.
With increased scrutiny around Antimicrobial Resistance (AMR) and the continued need for veterinary products for both prevention and treatment of disease when it occurs, over 75% of our R&D pipeline is focused on preventative vaccines and biologicals.
As an integrated solution provider, ECO Animal Health is pursuing Mycoplasma vaccines for pigs and poultry to complement its therapeutic offering against these pathogens. ECO is also collaborating with research institutions on the development of a unique vaccine based on innovative technologies for Marek’s disease virus (MDV), infectious bursal disease virus (IBDV), Newcastle disease virus (NDV) and infectious laryngotracheitis virus (ILTV) and on the development of a novel biopharmaceutical approach for the control of infectious bronchitis virus (IBV). ECO recently entered into a collaboration to develop novel vaccine approaches to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV).
Since veterinary surgeons will continue to require effective antibiotics, a unique, long-acting, injectable animal-only antibiotic (florfenicol), intended for use in pigs and by veterinary prescription, is at the early stages of development and an example of the ECO commitment to veterinary only medications.